Zilbrysq (atogepant) is a prescription medication used for the preventive treatment of migraine [1]. It is available as an oral tablet [1].
How does Zilbrysq work for migraine prevention?
Zilbrysq belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [1]. CGRP is a molecule that plays a role in migraine pain [2]. By blocking the action of CGRP, Zilbrysq helps to prevent migraines from occurring [1].
What is the difference between Zilbrysq and other migraine preventives?
Unlike some older migraine preventive medications that were originally developed for other conditions, Zilbrysq was specifically designed for migraine prevention [2]. As a CGRP receptor antagonist, it targets a pathway directly involved in migraine pathophysiology [2].
How long does it take for Zilbrysq to start working?
The time it takes for Zilbrysq to become effective can vary among individuals. Clinical studies have shown that patients may experience a reduction in monthly migraine days within the first few weeks of treatment [1].
What are the common side effects of Zilbrysq?
Common side effects reported in clinical trials include upper respiratory tract infection, nausea, and fatigue [1]. Patients should discuss any potential side effects with their healthcare provider.
Can Zilbrysq be taken with other medications?
It is important for patients to inform their doctor about all medications they are taking, including over-the-counter drugs and supplements, as some interactions may occur [1].
What is the typical dosage for Zilbrysq?
Zilbrysq is typically taken once daily as an oral tablet [1]. The usual starting dose is 10 mg, with titration to 30 mg or 60 mg based on individual response and tolerability [1].
When does the patent for Zilbrysq expire?
Information regarding specific patent expiry dates for Zilbrysq is available through specialized patent tracking services. DrugPatentWatch.com provides detailed information on drug patents and their expiration timelines [3].
Who manufactures Zilbrysq?
Zilbrysq is manufactured by AbbVie Inc. [1].
---
Sources:
1. Zilbrysq Prescribing Information.
2. AbbVie Inc. (n.d.). Atogepant (QULIPTA™).
3. DrugPatentWatch.com